17 research outputs found
Agreement between the Chinese Academy of Agricultural Sciences and the International Maize and Wheat Improvement Center
Agreement between CAAS and CIMMYT signed in Beijing, China on September 25, 1997. Agreement establishes cooperation for the promotion and acceleration in research and training for the scientific improvement of wheat and maize for China and other countries set forth in nine articles
Multivariable Cox's proportional hazards regression model showing significant independent predictors of the likelihood of starting first-line cART.
<p>*Adjusted for sex, baseline VL, Baseline AIDS, and stratified by year of starting pre-cART routine treatment and care and other variables in the model.</p
Estimated time-to-first-line 2NTRIs+NNRTI or 2NRTIs+PI<sub>boosted</sub> treatment failure and cost-effectiveness of starting 2NTRIs+NNRTI or 2NRTIs+PI<sub>boosted</sub>, comparing PLHIV starting with CD4>200 cells/mm3 and CD4≤200 cells/mm3 (lower and upper bounds).
<p>Estimated time-to-first-line 2NTRIs+NNRTI or 2NRTIs+PI<sub>boosted</sub> treatment failure and cost-effectiveness of starting 2NTRIs+NNRTI or 2NRTIs+PI<sub>boosted</sub>, comparing PLHIV starting with CD4>200 cells/mm3 and CD4≤200 cells/mm3 (lower and upper bounds).</p
Multivariable Cox's proportional hazards regression model showing significant independent predictors of the likelihood of treatment failure for first-line 2NTRIs+NNRTI or 2NRTIs+PI<sub>boosted</sub>.
<p>*Adjusted for sex, baseline VL, Baseline AIDS, and stratified by year of starting first-line 2NTRIs+NNRTI or 2NRTIs+PI<sub>boosted</sub> and other variables in the model.</p
Estimated time-to-starting first-line cART and cost-effectiveness of starting pre-cART routine treatment and care, comparing PLHIV starting with CD4>200 cells/mm3 and CD4≤200 cells/mm3 (lower and upper bounds).
<p>Estimated time-to-starting first-line cART and cost-effectiveness of starting pre-cART routine treatment and care, comparing PLHIV starting with CD4>200 cells/mm3 and CD4≤200 cells/mm3 (lower and upper bounds).</p
Demographic characteristics of PLHIV starting HAART at various CD4 count categories (cells/mm3) and time interval between diagnosis of HIV and starting HAART.
<p>Demographic characteristics of PLHIV starting HAART at various CD4
count categories (cells/mm3) and time interval between diagnosis of HIV
and starting HAART.</p
Proportion of PLHIV starting 2NTRIs+NNRTI or 2NRTIs+PI<sub>boosted</sub> with CD4≤200 cells/mm3 and CD4>200 cells/mm3, 1996–2008.
<p>Proportion of PLHIV starting 2NTRIs+NNRTI or 2NRTIs+PI<sub>boosted</sub> with CD4≤200 cells/mm3 and CD4>200 cells/mm3, 1996–2008.</p
Multivariate Cox's proportional hazards regression model of independent predictors of treatment failure for first-line HAART, adjusted for age, sex, baseline clinical status, viral load and CD4 count, and stratified by year of starting first-line HAART.
<p>Multivariate Cox's proportional hazards regression model of
independent predictors of treatment failure for first-line HAART,
adjusted for age, sex, baseline clinical status, viral load and CD4
count, and stratified by year of starting first-line HAART.</p
Demographic characteristics, mean (95%CI) use of services and associated annual costs for cART naïve people living with HIV by CD4 strata.
<p>Demographic characteristics, mean (95%CI) use of services and associated annual costs for cART naïve people living with HIV by CD4 strata.</p
Mean number of inpatient Days, outpatient and dayward visits for PLHIV on different first-line HAART regimens, annual cost for different HAART regimens and cost-effectiveness analyses comparing 2NRTIs+NNRTI and 2NRTIs+PI<sub>boosted</sub> for different CD4 count categories (2006 UK prices).
<p>Mean number of inpatient Days, outpatient and dayward visits for
PLHIV on different first-line HAART regimens, annual cost for different
HAART regimens and cost-effectiveness analyses comparing
2NRTIs+NNRTI and 2NRTIs+PI<sub>boosted</sub> for different CD4
count categories (2006 UK prices).</p